Comparative Pharmacology
Head-to-head clinical analysis: QUINACT versus QUINATIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUINACT versus QUINATIME.
QUINACT vs QUINATIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quinacrine is a 9-aminoacridine derivative that intercalates into DNA, inhibiting DNA replication and transcription, and also has antimalarial, anti-inflammatory, and antihelminthic properties. It inhibits phospholipase A2 and suppresses immune responses.
Quinine acts by interfering with the parasite's ability to break down hemoglobin, leading to accumulation of toxic heme and parasite death. It also inhibits nucleic acid and protein synthesis in the parasite.
100 mg orally three times daily.
600 mg (base) orally every 8 hours for 7 days; or 10 mg/kg (base) intravenously loading dose over 1 hour, then 0.02 mg/kg/min continuous infusion for 3 days, then switch to oral.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged in renal impairment; CrCl <30 mL/min: 24-40 hours)
Terminal elimination half-life 10-12 hours in healthy adults; prolonged in hepatic impairment.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal: ~20% unchanged; hepatic metabolism (CYP3A4) major route; biliary/fecal: ~80% as metabolites.
Category C
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)